Capmatinib identified as a promising candidate for repurposing against Mpox via in silico screening
Computer models identify potential new drugs to fight Mpox
This guideline provides an in silico study identifying capmatinib, nebivolol, and tucatinib as potential candidates for targeting MPXV thymi…
Researchers used computer simulations to identify three existing drugs that might be repurposed to treat Mpox infections.
Case report reviews capmatinib off-label use in two patients with radiation-induced MET-fusion glioma
Capmatinib Shows Promise Against Rare Brain Tumors
This case report with literature review describes off-label capmatinib use in two patients with radiation-induced gliomas harboring MET fusi…
A drug used for lung cancer is now helping some children with rare, deadly brain tumors live longer, even when standard treatments fail.
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…